Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT00716092
- Locations
- 🇩🇪
1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 503
- Registration Number
- NCT00621140
- Locations
- 🇮🇹
1218.16.39004 Boehringer Ingelheim Investigational Site, Catanzaro, Italy
🇮🇹1218.16.39008 Boehringer Ingelheim Investigational Site, Genova, Italy
🇮🇹1218.16.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 701
- Registration Number
- NCT00601250
- Locations
- 🇮🇳
1218.17.91002 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳1218.17.91005 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳1218.17.91012 Boehringer Ingelheim Investigational Site, Chennai, India
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1058
- Registration Number
- NCT00602472
- Locations
- 🇧🇪
1218.18.32006 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1218.18.32002 Boehringer Ingelheim Investigational Site, Huy, Belgium
🇨🇦1218.18.01003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 333
- Registration Number
- NCT00309608
- Locations
- 🇫🇷
1218.6.3305A Euraxi Pharma, Joue les Tours, France
🇸🇰1218.6.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
🇸🇰1218.6.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.